

Resource Summary Report

Generated by T1D on Aug 15, 2026

Selleck Chemicals LLC

RRID:SCR_003823

Type: Tool

Proper Citation

Selleck Chemicals LLC (RRID:SCR_003823)

Resource Information

URL: <http://www.selleckchem.com/>

Proper Citation: Selleck Chemicals LLC (RRID:SCR_003823)

Description: An Antibody supplier

Synonyms: Selleck Chemicals

Resource Type: commercial organization

Keywords: antibody, chemical supply, selleck chemicals

Resource Name: Selleck Chemicals LLC

Resource ID: SCR_003823

Alternate IDs: nlx_152457

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260815T182236+0000

Ratings and Alerts

No rating or validation information has been found for Selleck Chemicals LLC.

No alerts have been found for Selleck Chemicals LLC.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 235 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Gulla S, et al. (2026) MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer. *Cancer research*, 86(9), 2143.

Jin Y, et al. (2026) Dynamic microenvironment-regulated hydrogels releasing celastrol lead to urethral scarless repair. *Materials today. Bio*, 37, 102917.

Zhang W, et al. (2026) Antihypertensive Peptide ENWAAL Derived from Coix Glutelin and Its Effect on the Expression of SHR Renin-Angiotensin System. *Biomolecules*, 16(6).

Vostal AC, et al. (2026) Transgene Expression Kinetics and Replication Potential of Recombinant Adenovirus Serotype 4 in a Mouse Model and its Use as a Herpes Simplex Virus Vaccine. *bioRxiv : the preprint server for biology*.

Liu Y, et al. (2026) Immunogenic tumor cell death and T-cell-derived IFN- γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy. *Cell reports. Medicine*, 7(4), 102699.

Monti L, et al. (2026) Genome-wide mapping of DNA G-quadruplexes in *Trypanosoma brucei* chromatin reveals enrichment in coding regions and transcription start sites. *Nucleic acids research*, 54(12).

Maeda M, et al. (2026) CRISPR screen of human pancreatic cancer xenografts identifies a KLF5 proliferation vulnerability through epigenetic modifiers NCAPD2 and MTHFD1. *Molecular cancer*, 25(1).

Liu ZJ, et al. (2026) Adenylyl Cyclase 8 in Dorsal CA1 Neurons Prevents Depressive-Like Behaviors by Maintaining Neuronal Excitability and Glutamatergic Neurotransmission Through TIP39-PTH2R Signaling. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(10), e12170.

Liu W, et al. (2026) Astrocytic GSTM2-STAT3 interaction ameliorates the diabetes associated cognitive dysfunction via targeting mitochondrial defects and oxidative stress. *Redox biology*, 92, 104137.

Ahmadi M, et al. (2026) Integrated computational screening of FDA-approved anticancer drugs as novel HPV-16 E6 inhibitors in cervical cancer. *Scientific reports*, 16(1).

Kipp ZA, et al. (2026) Kinase signaling in liver disease via clinical-trial-on-a-PamChip: A distinctive methodology for drug mechanisms and personalized medicine. *The Journal of biological chemistry*, 302(5), 111379.

Khan MA, et al. (2026) Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression. *Cancer letters*, 638, 218160.

Vilarrubi A, et al. (2026) SMARCB1 Deficiency in Tumors Confers a Vulnerability to H3K27 Demethylase Inhibitors via Autophagy Disruption. *Cancer research*.

Yapindi L, et al. (2026) Dual Inhibition of TRIP13 and Aurora A Induces Mitotic DNA Damage and Concurrent Pyroptotic-Apoptotic Cell Death in Rb-Deficient Cancer Cells. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 3043.

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. *Molecular cancer therapeutics*, 25(3), 493.

Banerjee M, et al. (2026) FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response. *Cancer research*, 86(10), 2522.

Alhassan HH, et al. (2025) Elucidation of Artemisinin as a Potent GSK3 β Inhibitor for Neurodegenerative Disorders via Machine Learning-Driven QSAR and Virtual Screening of Natural Compounds. *Pharmaceuticals (Basel, Switzerland)*, 18(6).

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. *Cancer research*, 85(11), 1978.

Kim DK, et al. (2025) Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab. *Molecular cancer therapeutics*, 24(3), 354.

Özen I, et al. (2025) Traumatic brain injury causes early aggregation of beta-amyloid peptides and NOTCH3 reduction in vascular smooth muscle cells of leptomeningeal arteries. *Acta neuropathologica*, 149(1), 10.